Dermatology Times - Dr. Mark Lebwohl: "Secukinumab Superior to Etanercept for Plaque Psoriasis"

Secukinumab, an interleukin-17A inhibitor, was more effective in treating moderate-to-severe plaque psoriasis than the anti-tumor necrosis factor etanercept and current standard of care, according to a head-to-head phase 3 study.

New York, NY
 – October 14, 2013  –– 

"If you look at the peak response at 16 weeks, 87 percent of patients taking secukinumab achieved PASI 75, which is a very high response," said Mark Lebwohl, MD, Chairman of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai. "Seventy-seven percent of patients reached PASI 75 at 12 weeks of treatment, which was the primary end point of the study." Learn more